Status:
COMPLETED
Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects
Lead Sponsor:
Yale University
Collaborating Sponsors:
American Heart Association
Conditions:
Healthy Subjects
Eligibility:
All Genders
21-40 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Erythropoietin is made by the kidneys to stimulate red blood ce...
Detailed Description
Anti-apoptotic effects of erythropoietin in experimental myocardial infarction and ischemia-reperfusion injury suggest potential for therapeutic benefit in patients with acute MI. Before the therapeut...
Eligibility Criteria
Inclusion
- Age 21-40 years
- Able and willing to provide written informed consent
- Bleeding time \<10 minutes
Exclusion
- Any chronic medical disease
- Chronic or frequent over-the-counter or prescription medication use
- Hemoglobin \>15 gm/dl for both genders or \<13 gm/dl (men) or \<12 gm/dl (women)
- Platelet count \>400,000/µl or \<150,000/µl
- Blood pressure \> 140/90 mmHg
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00368238
Start Date
October 1 2005
End Date
July 1 2006
Last Update
August 24 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06510